News & Media
SK Life Science
Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company
General business
Strategic alliance and partnership opportunities
Media inquiries and PR
Grant and investigator initiated proposals
Sponsorship requests
Medical information inquiries or report adverse events
Phone: 1-866-OKSKLSI (657-5574)
Email: medicalinfo@sklsi.com
SK Life Science at a glance
-
Headquarters location
PARAMUS, NJ
-
R&D Begins
1993
-
Parent Company
SK Life Science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group
-
Number of employees
200+ EMPLOYEES
-
Disease Category Focus
CNS
-
Pipeline
8 compounds under clinical development
Newsroom
5/20/2020
Newly Published Study in Neurology Shows Cenobamate Significantly Reduced Seizure Frequency in Adults with Uncontrolled Partial-Onset (Focal) Seizures
Full release5/20/2020
SK life science Announces Results of Large, Open-Label Safety Study of Cenobamate Published in Epilepsia
Full release5/11/2020
SK life science Announces U.S. Availability of XCOPRI® (cenobamate tablets) CV for the Treatment of Partial-Onset Seizures in Adults
Full release5/05/2020
SK Life Science, Inc.’s Coronavirus Update
Full release3/26/2020
European Medicines Agency Accepts Arvelle Therapeutics’ Marketing Authorization Application for Cenobamate for the Adjunctive Treatment of Focal-Onset Seizures in Adults
Full release3/10/2020
SK life science Receives Schedule V Designation from DEA for XCOPRI® (cenobamate tablets)
Full release12/06/2019
SK life science to Present Latest Cenobamate Data at the American Epilepsy Society 2019 Annual Meeting
Full release12/02/2019
SK Life Science, Inc. Announces FDA Acceptance of IND Application for Anti-Epileptic Drug Candidate SKL24741
Full release11/21/2019
FDA Approves XCOPRI® (cenobamate tablets) CV, an Anti-Epileptic Drug (AED) from SK Biopharmaceuticals, Co., Ltd., and U.S. Subsidiary SK Life Science, Inc.
Full release11/13/2019
Results of a Randomized Study of the Safety and Efficacy of Cenobamate in Adults with Uncontrolled Focal Seizures Published in The Lancet Neurology
Full release